Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies
Open Access
- 14 April 2016
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 8 (6) , 679-683
Abstract
Biochemical experiments, animal models, and observational studies in humans all support a role of dipeptidyl peptidase 4 (DPP4) in the N‐terminal truncation of CXCL10, which results in the generation of an antagonist form of the chemokine that limits T‐cell and NK cell migration. Motivated by the ability to regulate lymphocyte trafficking in vivo, we conducted two prospective clinical trials to test the effects of DPP4 inhibition on CXCL10 processing in healthy donors and in chronic hepatitis C patients, a disease in which DPP4 levels are found to be elevated. Participants were treated daily with 100 mg sitagliptin, a clinically approved DPP4 inhibitor. Plasma samples were analyzed using an ultrasensitive single‐molecule assay (Simoa) to distinguish the full‐length CXCL101–77 from the NH2‐truncated CXCL103–77, as compared to the total CXCL10 levels. Sitagliptin treatment resulted in a significant decrease in CXCL103–77 concentration, a reciprocal increase in CXCL101–77, with only minimal effects on total levels of the chemokine. These data provide the first direct evidence that in vivo DPP4 inhibition in humans can preserve the bioactive form of CXCL10, offering new therapeutic opportunities for DPP4 inhibitors. Synopsis The N‐terminal truncation of CXCL10 by DPP4 results in the generation of an antagonist form of the chemokine that limits T‐cell and NK cell migration. This study shows for the first time that in vivo DPP4 inhibition in humans can preserve the bioactive form of CXCL10. Sitagliptin, an FDA‐approved DPP4 inhibitor for the treatment of type 2 diabetes, resulted in a decrease in the concentration of antagonist CXCL10 and a reciprocal increase in levels of the agonist form. Sitagliptin was effective in healthy subjects as well as in chronic HCV patients who have elevated levels of DPP4 and CXCL10. These results open new perspectives in the use of DPP4 inhibitors as therapeutic immune modulators.Keywords
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- Ligue Contre le Cancer
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 21 references indexed in Scilit:
- Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studiesEMBO Molecular Medicine, 2016
- Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapyNature Immunology, 2015
- Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and ImmunityAnnual Review of Immunology, 2014
- The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitisHepatology, 2013
- In Vivo DPP-4 Inhibition to Enhance Engraftment of Single-Unit Cord Blood Transplants in Adults with Hematological MalignanciesStem Cells and Development, 2013
- Discrimination of agonist and antagonist forms of CXCL10 in biological samplesClinical and Experimental Immunology, 2011
- Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCVJournal of Clinical Investigation, 2011
- Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral dosesClinical Pharmacology & Therapeutics, 2005
- Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis CBlood, 2005
- Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992